Overview
My focus is on medical dermatology, particularly patients who are immunocompromised. My clinical career in Dermatology has focused on dermatologic problems in HIV+ patients and solid organ transplant recipients, as well as patients who are immunocompromised for other medical conditions. I established the Duke Dermatology Transplant Clinic with the goal to provide early identification and prompt treatment of skin cancers in SOTRs by providing easy access, assessment of risk, patient education, early biopsy, field therapy for pre-cancers, medical therapeutic modification of risks if possible, and coordinated care with surgery, oncology or radiation therapy when indicated. In September 2022, I retired from the Duke Outpatient clinical service and now serve as an attending physician at the Durham VA Health System. I continue to provide Inpatient Dermatology for the Duke Health system as member of the consult team addressing the specialized multidisciplinary care of hospitalized patients with skin disease.
Key words: SOTR, Immunocompromised Patients, Skin Cancer, Inpatient Dermatology
Key words: SOTR, Immunocompromised Patients, Skin Cancer, Inpatient Dermatology
Current Appointments & Affiliations
Professor of Dermatology
·
2017 - Present
Dermatology,
Clinical Science Departments
Recent Publications
Paradoxical development of reactive squamous atypia and aggressive, invasive squamous cell carcinoma following 5-fluorouracil for field cancerization with concurrent immunomodulation.
Journal Article Clin Exp Dermatol · July 24, 2025 5-fluorouracil (5-FU) is a widely prescribed therapy for field cancerization. However, the emergence of cutaneous squamous cell carcinoma (cSCC) after 5-FU treatment is poorly described. We report five patients treated for field cancerization at four unive ... Full text Link to item CiteRecognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.
Journal Article JAAD Case Rep · April 2025 Full text Link to item CiteDe novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.
Journal Article J Am Acad Dermatol · October 2024 Full text Link to item CiteEducation, Training & Certifications
Duke University ·
1989
M.D.
Stanford University ·
1985
B.A.